Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody (original) (raw)

• Crepaldi T, Pollack AL, Prat M, Zborek A, Mostov K, Comoglio PM . Targeting of the SF/HGF receptor to the basolateral domain of polarized epithelial cells. J Cell Biol 1994; 125: 313–320.
  Article CAS Google Scholar
• Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 1991; 10: 2867–2878.
  Article CAS Google Scholar
• Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF . Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915–925.
  Article CAS Google Scholar
• Comoglio PM, Boccaccio C . Scatter factors and invasive growth. Semin Cancer Biol 2001; 11: 153–165.
  Article CAS Google Scholar
• Trusolino L, Bertotti A, Comoglio PM . MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834–848.
  Article CAS Google Scholar
• Petrelli A, Gilestro GF, Lanzardo S, Comoglio PM, Migone N, Giordano S . The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature 2002; 416: 187–190.
  Article CAS Google Scholar
• Qin S, Taglienti M, Nauli SM, Contrino L, Takakura A, Zhou J et al. Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease. J Clin Invest 2010; 120: 3617–3628.
  Article CAS Google Scholar
• Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009; 460: 904–908.
  Article CAS Google Scholar
• Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003; 63: 6272–6281.
  CAS Google Scholar
• Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T . Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 2009; 4: 5–11.
  Article Google Scholar
• Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006; 66: 283–289.
  Article CAS Google Scholar
• Zang ZJ, Ong CK, Cutcutache I, Yu W, Zhang SL, Huang D et al. Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. Cancer Res 2011; 71: 29–39.
  Article CAS Google Scholar
• Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 2008; 105: 692–697.
  Article CAS Google Scholar
• Lai AZ, Durrant M, Zuo D, Ratcliffe CD, Park M . Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer. J Biol Chem 2012; 287: 8048–8059.
  Article CAS Google Scholar
• Lefebvre J, Ancot F, Leroy C, Muharram G, Lemiere A, Tulasne D . Met degradation: more than one stone to shoot a receptor down. FASEB J 2012; 26: 1387–1399.
  Article CAS Google Scholar
• Liu X, Newton RC, Scherle PA . Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 2010; 16: 37–45.
  Article CAS Google Scholar
• Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006; 103: 2316–2321.
  Article CAS Google Scholar
• Foveau B, Ancot F, Leroy C, Petrelli A, Reiss K, Vingtdeux V et al. Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell 2009; 20: 2495–2507.
  Article CAS Google Scholar
• Nakagawa T, Tohyama O, Yamaguchi A, Matsushima T, Takahashi K, Funasaka S et al. E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci 2010; 101: 210–215.
  Article CAS Google Scholar
• Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012; 2: 270–287.
  Article CAS Google Scholar
• Comoglio PM, Giordano S, Trusolino L . Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7: 504–516.
  Article CAS Google Scholar
• Eder JP, Vande Woude GF, Boerner SA, LoRusso PM . Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15: 2207–2214.
  Article CAS Google Scholar
• Peruzzi B, Bottaro DP . Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006; 12: 3657–3660.
  Article CAS Google Scholar
• Stellrecht CM, Gandhi V . MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett 2009; 280: 1–14.
  Article CAS Google Scholar
• Vigna E, Pacchiana G, Mazzone M, Chiriaco C, Fontani L, Basilico C et al. ‘Active’ cancer immunotherapy by anti-Met antibody gene transfer. Cancer Res 2008; 68: 9176–9183.
  Article CAS Google Scholar
• Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68: 4360–4368.
  Article CAS Google Scholar
• Hedman H, Henriksson R . LRIG inhibitors of growth factor signalling—double-edged swords in human cancer? Eur J Cancer 2007; 43: 676–682.
  Article CAS Google Scholar
• Ordonez-Moran P, Huelsken J . Lrig1: a new master regulator of epithelial stem cells. EMBO J 2012; 31: 2064–2066.
  Article CAS Google Scholar
• Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, Carraway KL et al. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 2007; 27: 1934–1946.
  Article CAS Google Scholar
• Krumbach R, Schuler J, Hofmann M, Giesemann T, Fiebig HH, Beckers T . Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer 2011; 47: 1231–1243.
  Article CAS Google Scholar
• Oh YM, Song Y, Lee SB, Jeong Y, Kim B, Kim GW et al. A novel anti-c-Met antibody: therapeutic potential in cancer. Mol Cells (accepted).
• Stutz MA, Shattuck DL, Laederich MB, Carraway KL, Sweeney C . LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene 2008; 27: 5741–5752.
  Article CAS Google Scholar
• Wong VW, Stange DE, Page ME, Buczacki S, Wabik A, Itami S et al. Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nat Cell Biol 2012; 14: 401–408.
  Article CAS Google Scholar
• Benvenuti S, Comoglio PM . The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007; 213: 316–325.
  Article CAS Google Scholar
• Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
  Article CAS Google Scholar
• Petrelli A, Circosta P, Granziero L, Mazzone M, Pisacane A, Fenoglio S et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci USA 2006; 103: 5090–5095.
  Article CAS Google Scholar
• Pacchiana G, Chiriaco C, Stella MC, Petronzelli F, De Santis R, Galluzzo M et al. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J Biol Chem 2010; 285: 36149–36157.
  Article CAS Google Scholar
• Schelter F, Kobuch J, Moss ML, Becherer JD, Comoglio PM, Boccaccio C et al. A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. J Biol Chem 2010; 285: 26335–26340.
  Article CAS Google Scholar
• Ancot F, Leroy C, Muharram G, Lefebvre J, Vicogne J, Lemiere A et al. Shedding-Generated Met Receptor Fragments can be Routed to Either the Proteasomal or the Lysosomal Degradation Pathway. Traffic 2012; 13: 1261–1272.
  Article CAS Google Scholar
• Greenall SA, Gherardi E, Liu Z, Donoghue JF, Vitali AA, Li Q et al. Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET. PLoS One 2012; 7: e34658.
  Article CAS Google Scholar
• Asaoka Y, Tada M, Ikenoue T, Seto M, Imai M, Miyabayashi K et al. Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. Biochem Biophys Res Commun 2010; 394: 1042–1046.
  Article CAS Google Scholar
• Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104: 20932–20937.
  Article CAS Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039–1043.
  Article CAS Google Scholar
• Hamburger AW, Salmon SE . Primary bioassay of human tumor stem cells. Science 1977; 197: 461–463.
  Article CAS Google Scholar